ACLARIS THERAPEUTICS INC. - COMMON STOCK

Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

15 3 2021 06:00:01 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

25 2 2021 06:00:04 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

22 2 2021 06:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

10 2 2021 06:00:00 提供 Nasdaq GlobeNewswire

Aclaris Announces Pricing of Public Offering of Common Stock

20 1 2021 07:45:00 提供 Nasdaq GlobeNewswire

Aclaris Announces Proposed Public Offering of Common Stock

19 1 2021 15:01:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

19 1 2021 06:00:00 提供 Nasdaq GlobeNewswire